RP Bio Inc. (KOSDAQ:314140)

RP Bio Statistics

Total Valuation

RP Bio has a market cap or net worth of KRW 60.23 billion. The enterprise value is 66.05 billion.

Market Cap	60.23B
Enterprise Value	66.05B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

RP Bio has 8.67 million shares outstanding. The number of shares has decreased by -7.66% in one year.

Current Share Class	8.67M
Shares Outstanding	8.67M
Shares Change (YoY)	-7.66%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	61.75%
Owned by Institutions (%)	0.10%
Float	3.31M

Valuation Ratios

The trailing PE ratio is 19.79.

PE Ratio	19.79
Forward PE	n/a
PS Ratio	0.47
PB Ratio	0.57
P/TBV Ratio	0.58
P/FCF Ratio	8.31
P/OCF Ratio	4.73
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.62, with an EV/FCF ratio of 9.11.

EV / Earnings	21.76
EV / Sales	0.51
EV / EBITDA	6.62
EV / EBIT	20.55
EV / FCF	9.11

Financial Position

The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.20.

Current Ratio	1.34
Quick Ratio	0.71
Debt / Equity	0.20
Debt / EBITDA	2.09
Debt / FCF	2.88
Interest Coverage	2.88

Financial Efficiency

Return on equity (ROE) is 2.93% and return on invested capital (ROIC) is 1.56%.

Return on Equity (ROE)	2.93%
Return on Assets (ROA)	1.26%
Return on Invested Capital (ROIC)	1.56%
Return on Capital Employed (ROCE)	2.85%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.81
Inventory Turnover	4.39

Taxes

Income Tax	-246.64M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.28% in the last 52 weeks. The beta is 0.54, so RP Bio's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+9.28%
50-Day Moving Average	6,244.20
200-Day Moving Average	5,643.28
Relative Strength Index (RSI)	70.93
Average Volume (20 Days)	18,531

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RP Bio had revenue of KRW 129.09 billion and earned 3.03 billion in profits. Earnings per share was 351.25.

Revenue	129.09B
Gross Profit	11.30B
Operating Income	3.21B
Pretax Income	2.79B
Net Income	3.03B
EBITDA	9.97B
EBIT	3.21B
Earnings Per Share (EPS)	351.25

Balance Sheet

The company has 15.05 billion in cash and 20.87 billion in debt, giving a net cash position of -5.82 billion or -671.24 per share.

Cash & Cash Equivalents	15.05B
Total Debt	20.87B
Net Cash	-5.82B
Net Cash Per Share	-671.24
Equity (Book Value)	105.03B
Book Value Per Share	12,142.57
Working Capital	15.38B

Cash Flow

In the last 12 months, operating cash flow was 12.73 billion and capital expenditures -5.48 billion, giving a free cash flow of 7.25 billion.

Operating Cash Flow	12.73B
Capital Expenditures	-5.48B
Free Cash Flow	7.25B
FCF Per Share	836.84

Margins

Gross margin is 8.76%, with operating and profit margins of 2.49% and 2.35%.

Gross Margin	8.76%
Operating Margin	2.49%
Pretax Margin	2.16%
Profit Margin	2.35%
EBITDA Margin	7.73%
EBIT Margin	2.49%
FCF Margin	5.62%

Dividends & Yields

RP Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	7.66%
Shareholder Yield	n/a
Earnings Yield	5.04%
FCF Yield	12.04%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RP Bio has an Altman Z-Score of 1.9 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.9
Piotroski F-Score	6